Advancements in Research Grade Biosimilars Enable the Study of Therapeutic Antibodies

• Published in: The Journal of immunology (1950) Vol. 212; no. 1_Supplement; pp. 253 - 253_5051
• Main Authors: Cantor, Joseph, Gao, Guo-Jian, Rigaud, Stephanie, Wei, Ai-Li, Bazirgan, Omar, Verma, Shilpi
• Format: Journal Article
• Language: English
• Published: 01-05-2024
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.212.supp.0253.5051

Abstract Biosimilars for therapeutic antibodies contain identical variable sequences to FDA-approved antibodies. Recombinant BD research-grade biosimilars can be used to model several important aspects of major antibody therapies in use today. Our biosimilars with the huIgG1 (N297A) Fc mutation exhibit greatly reduced background binding and clarify the identification/study of therapeutic antibody target cell subsets. These flow cytometry reagents are available with many fluorochrome options to facilitate deeper phenotyping using large panels. Secreted targets (e.g., TNF-α) of therapeutic antibodies can either be bound in solution or in a membrane/cell-associated state; biosimilars may also be useful in studying this context-dependent target engagement. Alternatively, wildtype huIgG1 Fc biosimilars in no-azide/endotoxin-free (NA/LE) formats permit comparative mechanism-of-action (MOA) studies. Finally, biosimilars can be used in pre-blocking experiments to identify non-competing and competing clones used to study membrane target regulation, or gate on cell subsets defined by these targets in models of pre-exposure to therapeutic antibodies. In sum, our research-grade biosimilar antibodies can empower multiple avenues of research on therapeutic antibodies, which in turn are having major clinical impacts across medicine. For Research Use Only. Not for use in diagnostic or therapeutic procedures. BD is a trademark of Becton, Dickinson and Company. © 2023 BD. All rights reserved. NPM-2940